Introduction: Current prostate cancer risk calculators are limited in impact because only a probability of having prostate cancer is provided. We developed the next generation of prostate cancer risk calculator that incorporates life expectancy in order to better evaluate prostate cancer risk in context to a patient's age and comorbidity. Methods: We combined two cohorts to develop the new risk calculator. The first was 5638 subjects who all underwent a prostate biopsy for prostate cancer detection. The second was 979 men diagnosed with prostate cancer with long-term survival data. Two regression models were used to create multivariable nomograms and an online prostate cancer risk calculator was developed. Results: Of the 5638 patients who underwent a prostate biopsy, 629 (11%) were diagnosed with aggressive prostate cancer (Gleason Score 7[4+3] or more). Of the 979 patients who underwent treatment for prostate cancer, the 10-year overall survival (OS) was 49.6% (95% confidence interval [CI] 46.6-52.9). The first multivariable nomogram for cancer risk had a concordance index of 0.74 (95% CI 0.72, 0.76), and the second nomogram to predict survival had a concordance index of 0.71 (95% CI 0.69-0.72). The nextgeneration prostate cancer risk calculator was developed online and is available at: http://riskcalc.org/ProstateCA_Screen_Tool. Conclusions: We have developed the next-generation prostate cancer risk calculator that incorporates a patient's life expectancy based on age and comorbidity. This approach will better evaluate prostate cancer risk. Future studies examining other populations will be needed for validation.
Introduction
Screening for prostate cancer with the prostate-specific antigen (PSA) test alone has identified a high number of patients with indolent forms of prostate cancer, which has reduced the efficacy of screening for prostate cancer from randomized trials.
1,2 Based on these results, the U.S. Preventative Services Task Force initially recommended against using the PSA test for prostate cancer screening, 3 but have now reversed this decision. 4 In contrast, the American Society of Clinical Oncology (ASCO) reviewed the same body of evidence and concluded that prostate cancer screening with the PSA test should be considered among men with at least a 10-year life expectancy. 5 Thus, the practice of prostate cancer screening continues to be controversial between primary care physicians (PCPs) and cancer specialists.
To improve the positive and negative predictive value of the PSA test, prostate cancer risk calculators have been developed internationally. [6] [7] [8] These online instruments account for risk factors and other tumour markers for prostate cancer to improve the predictive ability of the PSA test. A key limitation of current prostate cancer risk calculators is that they provide a probability estimate for having prostate cancer and no thresholds for these estimates have been established. This makes it difficult to manage prostate cancer risk in the context of a patient's other potential competing comorbidities, which can affect life expectancy. This is particularly true for PCPs.
To improve the clinical utility of prostate cancer risk calculators, we developed the next generation of risk calculators, incorporating life expectancy based on comorbidity and 10-year survival rates of prostate cancer, and providing specific recommendations to physicians on what action is necessary for any given level of the PSA test.
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Methods

Study subjects
The study subjects consisted of two cohorts. The first included 5638 subjects who all underwent a prostate biopsy for prostate cancer detection from several different institutions. The second included 979 men diagnosed with prostate cancer in the early PSA era with long-term survival data.
The biopsy cohort was initially accrued from a multi-institutional prospective study evaluating the predictive accuracy of the Sunnybrook Prostate Cancer Risk Calculator. 6 Patients were eligible for inclusion if they had an abnormal PSA level (>2.6 ng/mL) or an abnormal digital rectal examination (DRE). From 2009-2014, patients were continually prospectively accrued from a single tertiary centre (Sunnybrook Health Sciences Centre) for further prostate cancer risk evaluation, including men with normal PSA levels. All patients underwent transrectal ultrasound-guided needle core biopsy (10-12 needle core samples). Patients were excluded if their PSA level was more than 50 ng/mL (n=109), if they had incomplete risk factor information (n=47), or if they were unable to provide consent (n=35).
The second prostate cancer cohort was based on an initial cohort of 979 men described in detail by Cowen et al. 9 In short, patients diagnosed with stage 1 or 2 prostate cancer between 1987 and 1989 were followed for at least 13 years of followup. Baseline demographic information, including age, comorbidity, tumour-related factors, and treatment details, were well-described. For this study, missing data was imputed in order to use all of the 979 patients. The dataset was imputed using multivariate imputation by chained equations (MICE) established and validated by Van Buuren et al. 10 This method approximates the posterior predicted distribution of each variable by regressing it on all other remaining variables. The first variable with missing observations, x 1 , is regressed on all remaining variables within the cohort, x 2 ,…,x k , where k is the total number of variables in the cohort. The missing values for the variable x 1 are replaced with the predicted values produced by the regression model. The imputation process is continued by creating regression models for each variable sequentially and inserting predicted values into the missing data slots until all missing values have been imputed exactly once for the first iteration. It should be noted that imputed data are included in the regression equations for subsequent imputations. Successive iterations are performed to re-impute and replace imputed values from previous iterations in order to obtain a stable estimate for each missing data point. As long as a sufficient number of iterations have been performed, the order in which the variables are imputed is irrelevant. 11 The MICE package in R uses five iterations for each imputation according to its default setting. This whole process is then repeated m times to give you m imputed data sets.
Primary endpoint and baseline information
The two endpoints used were the histological presence of high-grade, aggressive adenocarcinoma of the prostate biopsy specimen and OS. This was defined as patients with Prostate cancer risk calculator . Point values are summed for each variable and the total points is located on the total points scale (bottom axis). This corresponds to a probability value for having prostate cancer or aggressive prostate cancer. Symptom score is measured by total American Urological Association (AUA) symptom score. Prostate-specific antigen (PSA) is measured in ng/mL. Free:total PSA is measured by ratios.
Prostate cancer risk calculator stopping criterion. The model reduction process identifies the variable that has the smallest reduction in R2 and then removes it from the model; this process is continued until all variables are removed from the model. At each removal the concordance index is calculated and the process is stopped when the change is the concordance index is less than 0.001. Both models' performances are measured using the concordance index and calibration. The concordance index measures the models' ability to discriminate between those who are at higher risk by assigning a higher predicted probability than those who are at lower risk. The index ranges from 0-1, where 1 indicates a perfect discrimination and 0.5 indicates that the model is no better than chance. Calibration measures how close predicted probability is to the observed probability, where the 45° line indicates a perfect calibration. All calculations of the concordance index and calibration are corrected for optimism with bootstrapping. All statistical analysis was performed in R version 3. 1A) with a high degree of calibration (Fig. 1B) . Of the 979 patients who underwent treatment for prostate cancer, the 10-year OS was 49.6% (95% CI 46.6-52.9%). Patients were treated with watchful waiting, surgery, or radiotherapy. Within a multivariate model, age, marital status, smoking history, cholesterol, BMI, PSA level at diagnosis, bladder cancer, cardiac history, and CCI were all predic- tive of survival (Table 3) . A nomogram was constructed to predict 10-year OS with a concordance index of 0.71 (95% CI 0.69-0.72) ( Fig. 2A) with a high degree of calibration (Fig. 2B) . We then combined the two nomogram models to develop the next-generation prostate cancer risk calculator, which provides the risk of having aggressive, high-grade prostate cancer along with 10-year life expectancy. This new risk calculator also makes recommendations to PCPs based on the patient's risk factors, PSA level, and comorbidity to do "nothing further," "refer to a urologist," or repeat the PSA test in either two or six months (Fig. 3) . These recommendations and the threshold probabilities for having aggressive, high-grade prostate cancer and the survival rates were based on a consensus developed by the Prostate Cancer United Kingdom Prostate Risk Working Group. An expert panel of prostate cancer specialists were formed and a round table discussion based on consensus was used to develop the threshold probabilities. 12 The next generation prostate 13 Chen et al further added genetic risk scores based on host DNA single nucleotide polymorphisms of putative genes to the PCPT and found a higher rate of prostate cancer detection. 14 Vedder et al examined the addition of new serological markers for the European-based risk calculator and found an increase in predictive ability. 15 However, none of these updated calculators can specifically determine the potential number of life years lost from prostate cancer based on age and comorbidity.
Also, no risk calculators to date make any specific recommendations as to which action to take based on the results, because only a percentage risk for having any or aggressive prostate cancer is provided. The decision to proceed with a prostate biopsy is left with the patient and physician based on the risk provided. This has limited the impact of risk calculators in prostate cancer assessment. A limitation is the arbitrary nature to determine these thresholds, and future studies in validating these thresholds or developing new thresholds will be required.
We used the CCI to measure comorbidity for our prostate cancer cohort. Because longterm followup is needed among our prostate cancer cohort, it was necessary to use the CCI, which was used at the time of study inception. Current contemporary studies continue to use the CCI score and have shown its prognostic ability to predict survival for patients with prostate cancer. [16] [17] [18] A limitation of our study is the relatively small size (n=979) of the prostate cancer cohort. Although the cohort was derived from the PSA era, a proportion of patients did not undergo PSA testing, as it was early in its adoption. It is well-known that many larger datasets are available, but lack key data elements required for an effective prediction of life expectancy for patients with prostate cancer who are followed for all management strategies, including surgery, radiation, or conservative management. Data from large clinical trials, such as the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial and the European Randomized Study of Screening for Prostate Cancer (ERSPC) would be ideal, but are not readily available. From the 979 patients, Cowen et al used only 506 patients who had complete data and followup to estimate survival endpoints. 9 We were able to use the full dataset of 979 patients using new imputational methods. Nevertheless, larger datasets will be necessary to improve study power.
Also, other populations from the U.S. and Europe will be needed to further validate the predictive accuracy for prostate cancer risk and life expectancy models. Large populationbased datasets, such as the Surveillance, Epidemiology, and End-Results (SEER) program will be required. We have previously shown that the Sunnybrook risk calculator performed better than the Prostate Cancer Prevention Trial (PCPT) risk calculator. Other investigators will need to develop their own population cohort prostate cancer risk profile and survival in order to implement this approach. In this current 
Conclusion
We have developed a next-generation prostate cancer risk calculator for PCPs that incorporates a patient's life expectancy based on age and comorbidity. This approach will better evaluate prostate cancer risk than current risk calculators; however, future studies examining other populations will be needed for validation.
